Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COLOSAFE-DSR
- Development stage
- Unknown
- Lead developer
- Jointcare Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
COLOSAFE-DSR is a fixed-dose combination medication manufactured by Jointcare Pharmaceuticals, primarily indicated for the management of gastroesophageal reflux disease (GERD) and peptic ulcer disease. It consists of two active pharmacological agents: rabeprazole sodium and domperidone. Rabeprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly inhibiting the H+/K+-exchanging ATPase enzyme system at the secretory surface of the gastric parietal cell. Domperidone is a dopamine D2 receptor antagonist with prokinetic properties; it increases lower esophageal sphincter pressure and enhances gastroduodenal motility, thereby facilitating gastric emptying and providing antiemetic effects. This combination is particularly utilized in patients who do not respond adequately to PPI monotherapy, addressing both acid overproduction and impaired gastric motility. It is formulated as a sustained-release capsule for oral administration.
- Brand names
- COLOSAFE-DSR
- Other names
- domperidone + rabeprazoleRabeprazole Sodium and Domperidone Sustained Release Capsules
02
Targets
DRD2 (Dopamine D2 Receptor)ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on COLOSAFE-DSR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COLOSAFE-DSR.